State Street’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

State Street’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-729	Closed	-$4K	–	3748
2016 Q3	$4K	Hold	729	–	–	﹤0.01%	3593
2016 Q2	$7K	Hold	729	–	–	﹤0.01%	3713
2016 Q1	$8K	Hold	729	–	–	﹤0.01%	3708
2015 Q4	$11K	Hold	729	–	–	﹤0.01%	3694
2015 Q3	$12K	Hold	729	–	–	﹤0.01%	3694
2015 Q2	$14K	Hold	729	–	–	﹤0.01%	3694
2015 Q1	$14K	Hold	729	–	–	﹤0.01%	3651
2014 Q4	$22K	Sell	729 -85	-10%	-$2.45K	﹤0.01%	3643
2014 Q3	$29K	Hold	814	–	–	﹤0.01%	3620
2014 Q2	$36K	Hold	814	–	–	﹤0.01%	3576
2014 Q1	$40K	Hold	814	–	–	﹤0.01%	3574
2013 Q4	$30K	Sell	814 -175	-18%	-$16.6K	﹤0.01%	3577
2013 Q3	$102K	Sell	989 -68	-6%	-$7.47K	﹤0.01%	3461
2013 Q2	$82K	Buy	+1,057	New	+$101K	﹤0.01%	3392

Other funds holding IMUC

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street's IMUC Position: Q4 2016 in Review

State Street sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 729 shares — an estimated $4K sold.

State Street first reported a position in IMUC in Q2 2013 and held it in 14 quarters. The position peaked at $102K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

State Street reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
State Street sold 729 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $4K.
State Street first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 14 quarters.
State Street's ImmunoCellular Therapeutics, Ltd. position peaked at $102K in Q3 2013.
16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on State Street's 13F filing for Q4 2016, filed 9 Feb 2017.